Groups or subgroups | Studies (Subjects) | P Heterogeneity | SMD (95% CI) | P SMD |
---|---|---|---|---|
Triglycerides | ||||
 All | 38 (4213) | <  0.001 | − 0.76 (− 0.91, − 0.61) | <  0.001 |
 Coronary artery disease | 7 (790) | <  0.001 | − 0.52 (− 0.88, − 0.16) | <  0.01 |
 Cerebrovascular disease | 16 (2218) | <  0.001 | − 0.94 (− 1.13, − 0.74) | <  0.001 |
 Diabetes | 9 (695) | 0.001 | − 0.58 (− 0.87, − 0.29) | <  0.001 |
 Hyperlipidemia | 5 (444) | <  0.001 | − 0.87 (− 1.54, − 0.20) | <  0.05 |
 Low-dose (≤ 20 mL) | 13 (1257) | <  0.001 | − 0.90 (− 1.15, − 0.66) | <  0.001 |
 High-dose (>  20 mL) | 25 (2956) | <  0.001 | − 0.69 (− 0.88, − 0.50) | <  0.001 |
 Short-duration (≤ 2 weeks) | 20 (2472) | <  0.001 | − 0.76 (− 0.99, − 0.53) | <  0.001 |
 Long-duration (>  2 weeks) | 17 (1661) | <  0.001 | − 0.80 (− 0.99, − 0.61) | <  0.001 |
Total cholesterol | ||||
 All | 41 (4781) | <  0.001 | − 1.29 (− 1.56, − 1.03) | <  0.001 |
 Coronary artery disease | 7 (982) | <  0.001 | − 1.12 (− 1.85, − 0.40) | <  0.01 |
 Cerebrovascular disease | 18 (2390) | <  0.001 | − 1.53 (− 1.94, − 1.13) | <  0.001 |
 Diabetes | 9 (695) | <  0.001 | − 1.28 (− 1.87, − 0.70) | <  0.001 |
 Hyperlipidemia | 6 (648) | 0.08 | −1.16 (− 1.46, − 0.86) | <  0.001 |
 Low-dose (≤ 20 mL) | 13 (1449) | <  0.001 | − 1.13 (− 1.49, − 0.78) | <  0.001 |
 High-dose (>  20 mL) | 28 (3332) | <  0.001 | − 1.38 (− 1.73, − 1.02) | <  0.001 |
 Short-duration (≤ 2 weeks) | 21 (2544) | <  0.001 | − 1.12 (− 1.38, − 0.86) | <  0.001 |
 Long-duration (>  2 weeks) | 19 (2157) | <  0.001 | − 1.42 (− 1.92, − 0.92) | <  0.001 |
LDL-C | Â | Â | Â | Â |
 All | 38 (4412) | <  0.001 | − 0.76 (− 0.93, − 0.59) | <  0.001 |
 Coronary artery disease | 8 (1012) | <  0.001 | − 0.72 (− 1.15, − 0.30) | 0.001 |
 Cerebrovascular disease | 16 (2183) | <  0.001 | − 0.94 (− 1.24, − 0.64) | <  0.001 |
 Diabetes | 7 (503) | 0.02 | − 0.56 (− 0.86, − 0.26) | <  0.001 |
 Hyperlipidemia | 5 (444) | 0.34 | −0.54 (− 0.74, − 0.34) | <  0.001 |
 Low-dose (≤ 20 mL) | 14 (1579) | <  0.001 | − 0.79 (− 1.05, − 0.53) | <  0.001 |
 High-dose (>  20 mL) | 24 (2833) | <  0.001 | − 0.74 (− 0.96, − 0.52) | <  0.001 |
 Short-duration (≤ 2 weeks) | 18 (2115) | <  0.001 | − 0.71 (− 0.92, − 0.50) | <  0.001 |
 Long-duration (>  2 weeks) | 19 (2217) | <  0.001 | −0.85 (− 1.11, − 0.58) | <  0.001 |
HDL-C | ||||
 All | 32 (3616) | <  0.001 | 0.70 (0.41, 0.98) | <  0.001 |
 Coronary artery disease | 5 (500) | <  0.001 | 0.75 (−0.00, 1.50) | 0.05 |
 Cerebrovascular disease | 17 (2318) | <  0.001 | 0.98 (0.55, 1.41) | <  0.001 |
 Diabetes | 4 (288) | 0.10 | 0.32 (−0.07, 0.70) | 0.10 |
 Hyperlipidemia | 5 (444) | <  0.001 | 0.19 (−0.32, 0.69) | 0.47 |
 Low-dose (≤ 20 mL) | 11 (1032) | <  0.01 | 0.53 (0.33, 0.73) | <  0.001 |
 High-dose (>  20 mL) | 21 (2584) | <  0.001 | 0.79 (0.38, 1.21) | <  0.001 |
 Short-duration (≤ 2 weeks) | 16 (2070) | <  0.001 | 0.92 (0.55, 1.29) | <  0.001 |
 Long-duration (>  2 weeks) | 15 (1466) | <  0.001 | 0.51 (0.07, 0.95) | 0.02 |